Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $333.38K rose 264.5% year over year, ahead of the -28.9% change in trailing-twelve-month research & development. Sequentially, it rose 539.7% from the prior quarter. Over 3 fiscal years it compounded at -42.6% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +264.5% holds above the trailing-twelve-month pace of -28.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 254.92K USD
- Year-over-year change
- -64.9%
- 4-year CAGR
- -38.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 254.92K | -64.9% |
| FY2024 | 2024-12-31 | 726.23K | -19.1% |
| FY2023 | 2023-12-31 | 898.1K | -33.4% |
| FY2022 | 2022-12-31 | 1.35M | -22.3% |
| FY2021 | 2021-12-31 | 1.74M | — |
Research & Development vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 research & development of $496.84K is the lowest of the 2 companies compared; the peer median is $9.74M.
- Its year-over-year change of -28.9% is the lowest of 2, against a peer median of -1.3%.
- Over three fiscal years its annual growth of -42.6% compares with a peer median of +2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.74M | -1.3% | +2.8% | — | |
| LTM Mar 2026 | $496.84K | -28.9% | -42.6% | — | |
| Peer median (excluding LIXT) | $9.74M | -1.3% | +2.8% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.74M | 1.35M | 898.1K | 726.23K | 254.92K |
| Selling, General & Admin | 4.98M | 4.96M | 4.19M | 2.85M | 4.85M |
| Operating Expenses | 6.72M | 6.31M | 5.09M | 3.57M | 5.11M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (6.72M) | (6.3M) | (5.07M) | (3.57M) | (6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.72M) | (6.31M) | (5.09M) | (3.57M) | (5.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 626 | 11.2K | 17.49K | 7.05K | 7.39K |
| Interest Expense | 7.41K | 8.88K | 16.23K | 16.82K | 9.16K |
| Other Income / Expenses | (7.95K) | (1.05K) | 3.21K | (13.18K) | (901.9K) |
| Income Before Tax | (6.73M) | (6.31M) | (5.09M) | (3.59M) | (6.01M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.73M) | (6.31M) | (5.09M) | (3.59M) | (6.01M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.00) | (4.00) | (2.66) | (1.59) | (1.26) |
| EPS (Diluted) | (5.00) | (4.00) | (2.66) | (1.59) | (1.26) |
| Weighted Avg Shares | 1.35M | 1.58M | 1.91M | 2.25M | 48.41M |
| Weighted Avg Shares (Diluted) | 1.35M | 1.58M | 1.92M | 2.25M | 48.41M |
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.